CHRS (Coherus Oncology) ROCE % : -128.56% (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Coherus Oncology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Coherus Oncology's annualized ROCE % for the quarter that ended in Mar. 2025 was -128.56%.

Coherus Oncology ROCE % Historical Data

The historical data trend for Coherus Oncology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus Oncology ROCE % Chart

Coherus Oncology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

31.69

-43.66

-60.57

-61.79

24.03

Coherus Oncology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-99.29	-13.89	-10.23	-96.75	-128.56

Coherus Oncology ROCE % Calculation

Coherus Oncology's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	55.665	/	( ( (629.604 - 331.771)	+	(448.533 - 282.981) )	/ 2 )
	=	55.665	/	( (297.833	+	165.552)	/ 2 )
	=	55.665	/	231.6925
	=	24.03 %

Coherus Oncology's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-180.992	/	( ( (448.533 - 282.981)	+	(371.066 - 255.042) )	/ 2 )
	=	-180.992	/	( ( 165.552	+	116.024 )	/ 2 )
	=	-180.992	/	140.788
	=	-128.56 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Coherus Oncology (NAS:CHRS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Coherus Oncology ROCE % Related Terms

Thank you for viewing the detailed overview of Coherus Oncology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus Oncology Inc (NAS:CHRS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

8C5:Germany

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Executives

Mats Wahlstrom	director	500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Dennis M Lanfear	director, officer: President and CEO	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell	officer: Chief Financial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael	officer: See Remarks	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider	officer: Chief Commercial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton	director	46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler	officer: Chief Scientific Officer	333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti	officer: Chief, Quality & Compliance	COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret	officer: Chief Financial Officer	ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper	director	150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson	director	ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025